UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reagents for Astatination of Biomolecules. 5. Evaluation of Hydrazone Linkers in 211At- and 125I-Labeled closo-Decaborate(2-) Conjugates of Fab′ as a Means of Decreasing Kidney Retention

Bioconjugate chemistry, 2011-05, Vol.22 (6), p.1089-1102

2011

Volltextzugriff (PDF)

Transforming Growth Factor-β–Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition

Clinical cancer research, 2009-12, Vol.15 (24), p.7634-7641

2009

Volltextzugriff (PDF)

Plasma Fatty Acids as Surrogate for Prostate Levels

Nutrition and cancer, 2018-01, Vol.70 (1), p.45-50

2018

Volltextzugriff (PDF)

Metastatic Progression of Prostate Cancer and E-Cadherin

The American journal of pathology, 2011-07, Vol.179 (1), p.400-410

2011

Volltextzugriff (PDF)

Tumor cell dormancy: An NCI workshop report

Cancer biology & therapy, 2007-09, Vol.6 (9), p.1492-1500

2007

Volltextzugriff (PDF)

Inhibition of Androgen-independent Growth of Prostate Cancer Xenografts by 17β-Estradiol

Clinical cancer research, 2002-04, Vol.8 (4), p.1003-1007

2002

Volltextzugriff (PDF)

Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase

The American journal of pathology, 2007, Vol.170 (6), p.2100-2111

2007

Volltextzugriff (PDF)

Are Circulating Phospholipid Fatty Acids a Reasonable Surrogate for Target Tissue Levels In The Prostate?

Nutrition and cancer, 2017-12, Vol.70 (1), p.45-50

2017

Volltextzugriff (PDF)

Abstract 5205: CCND1 is a miR-193b target in prostate cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5205-5205

2014

Volltextzugriff (PDF)

Abstract 1685: In vivo efficacy of PSMA ADC in combination with enzalutamide in castration-resistant prostate cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1685-1685

2015

Volltextzugriff (PDF)

Abstract IA21: AR is ablated: Now what? Targeting the double-negative phenotype

Cancer research (Chicago, Ill.), 2018-08, Vol.78 (16_Supplement), p.IA21-IA21

2018

Volltextzugriff (PDF)

Abstract 735: Evaluation of cabozantinib in combination with abiraterone, enzalutamide or docetaxel in a castration-resistant prostate cancer xenograft in vivo

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.735-735

2014

Volltextzugriff (PDF)

Abstract 737: Assessment of cabozantinib activity in diverse prostate cancer xenograft models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.737-737

2014

Volltextzugriff (PDF)

Abstract 1214: Preclinical models of prostate cancer: New patient-derived xenografts for preclinical studies and evaluation of prostate cancer biology

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1214-1214

2014

Volltextzugriff (PDF)

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models

Clinical cancer research, 2016-07, p.clincanres.0137.2016

2016

Volltextzugriff (PDF)

Abstract A109: Radium-223 dichloride inhibits tumor growth and tumor-induced bone growth in osteoblastic prostate cancer models

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A109-A109

2015

Volltextzugriff (PDF)

Abstract 1718: The importance of clinically relevant rapid autopsy specimens and LuCaP patient-derived xenograft models to interrogate the heterogeneous and evolving treatment resistance of castration-resistant prostate cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1718-1718

2015

Volltextzugriff (PDF)

Abstract 3447: Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3447-3447

2015

Volltextzugriff (PDF)

Abstract 4313: Abiraterone acetate (AA) treatment of prostate cancer patient-derived xenografts (PDX) demonstrates heterogeneity of responses and identifies potential biomarkers of adaptive resistance

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4313-4313

2015

Volltextzugriff (PDF)

Abstract 2133: In vivo efficacy of PSMA ADC in castration-resistant prostate cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2133-2133

2013

Volltextzugriff (PDF)

Abstract 849: Cabozantinib (XL184) inhibits growth of prostate cancer in the bone and results in an altered bone environment

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.849-849

2012

Volltextzugriff (PDF)

Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer

Nature medicine, 2016-02, Vol.22 (4), p.369-378

2016

Volltextzugriff (PDF)

Abstract 4011: Single cell transcriptomic analysis identified a potential dormant signature in prostate cancer disseminated tumor cells

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4011-4011

2014

Volltextzugriff (PDF)

Abstract 1937: Nemo-like kinase expression is altered during prostate cancer progression

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1937-1937

2011

Volltextzugriff (PDF)

Abstract PR6: Cabozantinib (XL184) inhibits androgen-sensitive and castration-resistant prostate cancer in the bone and increases bone formation in non-tumored bones

Cancer research (Chicago, Ill.), 2012-02, Vol.72 (4_Supplement), p.PR6-PR6

2012

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Complete

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Englisch
(78)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reagents for Astatination of Biomolecules. 5. Evaluation of Hydrazone Linkers in 211At- and 125I-Labeled closo-Decaborate(2-) Conjugates of Fab′ as a Means of Decreasing Kidney Retention

Transforming Growth Factor-β–Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition

Plasma Fatty Acids as Surrogate for Prostate Levels

Metastatic Progression of Prostate Cancer and E-Cadherin

Tumor cell dormancy: An NCI workshop report

Inhibition of Androgen-independent Growth of Prostate Cancer Xenografts by 17β-Estradiol

Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase

Are Circulating Phospholipid Fatty Acids a Reasonable Surrogate for Target Tissue Levels In The Prostate?

Abstract 5205: CCND1 is a miR-193b target in prostate cancer

Abstract 1685: In vivo efficacy of PSMA ADC in combination with enzalutamide in castration-resistant prostate cancer

Abstract IA21: AR is ablated: Now what? Targeting the double-negative phenotype

Abstract 735: Evaluation of cabozantinib in combination with abiraterone, enzalutamide or docetaxel in a castration-resistant prostate cancer xenograft in vivo

Abstract 737: Assessment of cabozantinib activity in diverse prostate cancer xenograft models

Abstract 1214: Preclinical models of prostate cancer: New patient-derived xenografts for preclinical studies and evaluation of prostate cancer biology

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models

Abstract A109: Radium-223 dichloride inhibits tumor growth and tumor-induced bone growth in osteoblastic prostate cancer models

Abstract 1718: The importance of clinically relevant rapid autopsy specimens and LuCaP patient-derived xenograft models to interrogate the heterogeneous and evolving treatment resistance of castration-resistant prostate cancer

Abstract 3447: Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models

Abstract 4313: Abiraterone acetate (AA) treatment of prostate cancer patient-derived xenografts (PDX) demonstrates heterogeneity of responses and identifies potential biomarkers of adaptive resistance

Abstract 2133: In vivo efficacy of PSMA ADC in castration-resistant prostate cancer

Abstract 849: Cabozantinib (XL184) inhibits growth of prostate cancer in the bone and results in an altered bone environment

Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer

Abstract 4011: Single cell transcriptomic analysis identified a potential dormant signature in prostate cancer disseminated tumor cells

Abstract 1937: Nemo-like kinase expression is altered during prostate cancer progression

Abstract PR6: Cabozantinib (XL184) inhibits androgen-sensitive and castration-resistant prostate cancer in the bone and increases bone formation in non-tumored bones

Aktive Filter

Suchergebnisse filtern